Alpha Wave Global and Integrated led a $40m Series A round in Transcend Therapeutics.

Alpha Wave Global, a provider of asset classes, themes, and geographies from venture capital to public markets to credit, and Integrated, a venture capital firm, led a $40m Series A round in Transcend Therapeutics, a provider of novel pharmaceuticals for the critical care market, with participation from Global Founders Capital, Emerald Development Managers, and AlleyCorp. "We need new and innovative approaches to dealing with the mental health crisis, and Transcend is unique in that it has the team and a well-characterized lead compound to make a meaningful impact in the lives of millions. We are thrilled to lead this Series A investment round and confident that this funding will accelerate Transcend's work to bring methylone to market sooner, while beginning to build out a pipeline of other promising compounds," Rick Gerson, Alpha Wave Global Co-Founder, Chairman, and CIO.